Press Release

ADME Toxicology Testing Market to grow with a CAGR of 9.30% through 2029

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global ADME Toxicology Testing Market in the forecast period 2025-2029

According to TechSci Research report, “Global ADME Toxicology Testing Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2019-2029”, Global ADME Toxicology Testing Market has valued at USD 8.30 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.30% through 2029. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market. The demand for personalized medicine is a significant driver of the Global ADME (Absorption, Distribution, Metabolism, and Excretion) Toxicology Testing Market. Personalized medicine, also known as precision medicine, is an innovative approach to healthcare that tailor’s medical treatment and drug therapies to individual patients based on their genetic, environmental, and lifestyle factors. Personalized medicine often relies on genetic information to customize treatment plans. Genetic variations can significantly impact how individuals metabolize drugs and respond to treatment. ADME testing is essential to assess how drugs will be absorbed, distributed, metabolized, and excreted in patients with specific genetic profiles. Pharmacogenomics is a key component of personalized medicine that focuses on how an individual's genetic makeup influences their response to medications. ADME toxicology testing plays a crucial role in understanding the relationship between genetic variations and drug metabolism. ADME testing helps determine the optimal dosing regimens for individual patients. Understanding how a drug behaves in the body allows healthcare providers to prescribe the right drug at the right dose, improving therapeutic outcomes and minimizing adverse effects. Personalized medicine aims to enhance patient safety by minimizing the risk of adverse drug reactions. ADME testing helps identify potential safety concerns and tailor treatment plans to reduce these risks.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global ADME Toxicology Testing Market

 

In March 2023, Agilent Technologies Inc. has announced its acquisition of e-MSion, an emerging company responsible for developing the innovative ExD cell, a breakthrough electron capture dissociation (ECD) technology. The ExD cell, a compact attachment for mass spectrometers, empowers biological researchers to expedite the development of biotherapeutic solutions for various diseases. It accomplishes this by facilitating a more comprehensive and precise breakdown of the chemical bonds within complex biomolecules. This enhanced process yields more exhaustive, precise, and intricate structural data from these biomolecules. What's noteworthy is that the ExD cell is compatible with commonly used laboratory instruments, including Agilent's 6500 LC/Q-TOF series. This means that the powerful characterization technology, previously limited to a select few high-end mass spectrometers, will now become more accessible to a broader spectrum of laboratories and biopharmaceutical researchers around the world.

Inter-individual variability, which refers to differences in the way individuals respond to drugs and toxic substances, is a significant challenge in the Global ADME (Absorption, Distribution, Metabolism, and Excretion) Toxicology Testing Market. Inter-individual variability impacts dosing regimens. It's essential to determine the right dose for each patient, as factors like genetics, age, gender, and underlying health conditions can influence drug metabolism. ADME testing must account for variability in drug metabolism and toxicity responses. This involves assessing how different individuals may experience varying degrees of efficacy and safety when taking the same drug. Genetic variations, such as single nucleotide polymorphisms (SNPs), play a crucial role in inter-individual variability. These genetic differences can affect drug metabolism enzymes, transporters, and receptors, leading to differing drug responses. Variability in drug responses can result in complex drug-drug interactions. Assessing these interactions is challenging, especially in the presence of diverse patient profiles. Clinical trial design must account for inter-individual variability. Larger and more diverse patient populations are often required to detect these variations and ensure that drug efficacy and safety are adequately evaluated. Population pharmacokinetics is a method used to model drug behavior across diverse patient populations. This approach is used to address inter-individual variability in drug pharmacokinetics and optimize dosing.

Global ADME Toxicology Testing Market is segmented based on Technology, Application, Method, and by region.

Based on the Application, Global ADME Toxicology Testing Market is segmented into Neurotoxicity, Renal Toxicity, Systemic Toxicity, Hepatotoxicity, and others. Hepatotoxicity, in the context of ADME (Absorption, Distribution, Metabolism, and Excretion) Toxicology Testing, refers to the assessment of potential liver toxicity caused by drug compounds or other substances. The liver plays a central role in the metabolism of drugs and xenobiotics (foreign substances), and it is susceptible to damage by certain compounds. Evaluating hepatotoxicity is crucial to ensure the safety of drugs and to understand how they may affect the liver. Hepatotoxicity is a leading cause of drug withdrawals and post-market safety concerns. Therefore, it's crucial to identify and mitigate the risks associated with liver toxicity during the drug development process.

Based on Region, North America held the largest share in the Global ADME Toxicology Testing Market. North American companies and research institutions have been at the forefront of developing and implementing advanced ADME testing technologies and methodologies. This technological leadership attracts clients from around the world seeking state-of-the-art testing services. The region fosters collaboration and networking among academia, industry, and government agencies. This environment of cooperation accelerates research, innovation, and the adoption of new ADME testing solutions. North America has a well-educated and skilled workforce, including scientists, researchers, and laboratory technicians, which is essential for conducting complex ADME testing. High prevalence of diseases, a growing aging population, and the constant demand for novel pharmaceuticals drive the need for ADME toxicology testing in North America.

 

Some of the major companies operating in the Global ADME Toxicology Testing Market include:

  • Thermo Fisher Scientific Inc.
  • Promega Corporation
  • Agilent Technologies, Inc.
  • Curia Global, Inc.
  • Dassault Systèmes
  • Beckman Coulter, Inc., (Danaher)
  • Catalent, Inc
  • Charles River Laboratories
  • GE HealthCare
  • Miltenyi Biotec

 

Download Free Sample Report

Customers can also request 10% free customization on this report

 

“Certain areas, particularly in North America, are projected to exert significant demand for ADME Toxicology Testing. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global ADME Toxicology Testing Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

ADME Toxicology Testing Market by Technology (Cell Culture, OMICS Tech, High Throughput, Molecular Imaging), By Application (Neurotoxicity, Renal Toxicity, Systemic Toxicity, Hepatotoxicity, others), By Method (Cellular Assay, In-Silica, Biochemical Assay, Ex-vivo), By Region, By Competition Forecast & Opportunities, 2019-2029 has evaluated the future growth potential of Global ADME Toxicology Testing Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global ADME Toxicology Testing Market.

 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News